Put New Heart Failure Guidelines in Perspective
We’re used to “triple therapy” for HFrEF...an ACEI or ARB, evidence-based beta-blocker (carvedilol, etc), and aldosterone antagonist (spironolactone, etc)...to reduce hospitalizations and death.
Now Entresto (sacubitril/valsartan) is preferred INSTEAD of an ACEI or ARB when possible...since it prevents hospitalization or CV death in about 1 in 21 patients versus an ACEI.
Guidelines also suggest “QUAD therapy”...adding an SGLT2 inhibitor (Farxiga, etc) to triple therapy, regardless of diabetes. This prevents hospitalization or CV death in about 1 in 20 patients.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: PA includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote